Recall of Clindamycin Injection USP ADD-Vantage vials by Alvogen: Presence of microbial growth

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

ISSUE: Alvogen is voluntarily recalling seven lots of Clindamycin Injection USP ADD-Vantage Vials to the hospital/retail level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the product. Clindamycin Injection is manufactured for Alvogen by Hospira Inc., a Pfizer Company.

In the event that impacted product is administered, there is a reasonable probability that the patient may experience adverse events, ranging from fever, chills and malaise, to severe adverse events including systemic invasive mycoses or systemic bacterial sepsis. The possibility of a breach in sterility assurance in distributed product, while remote, cannot be eliminated. To date, Alvogen has not received any reports of adverse events associated with use of the product.

BACKGROUND: Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible bacteria. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. See the company announcement for list of product lot n...

Recommended for you

  • FDA Drug Updates
  • 1 comment

FDA approves Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I recall of Zenith Alpha Thoracic Endovascular Graft by Cook Medical – thrombus may form inside the device

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of lorazepam oral concentrate, USP 2mg/mL - defect in the dropper markings

Read more
  • FDA Drug Updates
  • no comment

New targeted treatment approved for relapsed or refractory acute myeloid leukemia

Read more
  • MedWatch Drug Updates
  • no comment

Recall of pravastatin sodium tablets by International Laboratories: Mislabeled and contained different drug

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Potential complication associated with liquid-filled intragastric balloon systems

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA Alert: Lack of sterility assurance for sterile drug products from Vital Rx, dba Atlantic Pharmacy and Compounding

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of all liquid products manufactured by PharmaTech: Risk of product contamination

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I recall of Penumbra 3D Revascularization device by Penumbra: delivery wire may break or separate during use

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for Hepatitis C

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA advise not to use any liquid product manufactured by PharmaTech due to possible contamination

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Nerlynx (neratinib) for breast cancer

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA Investigation: Hypersensitivity reaction due to ungraded ingredient in curcumin emulsion for Injection by ImprimisRx

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA warning against the use of Balguti Kesaria Ayurvedic Medicine due to risk of lead poisoning

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Endari (L-glutamine) for sickle cell disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Novopen Echo Insulin Delivery Device by Novo Nordisk: Chemical exposure may damage cartridge holder

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Atar Extension Cables by Oscor- cable malfunction interrupting the pacing system

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Diocto Liquid and Diocto Syrup by Rugby Laboratories: Risk of product contamination

Read more
  • FDA Drug Updates
  • 1 comment

FDA expands approved use of Imbruvica (ibrutinib) for chronic graft versus host disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of cyclobenzaprine and amantadine by Apace Packaging due to a potential mislabeling

Read more
  • MedWatch Drug Updates
  • 1 comment

Safety alert against compounded triamicinolone and moxifloxacin intravitreal Inj by Guardian Pharmacy Services

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Haegarda (C1 esterase inhibitor) for Hereditary Angioedema

Read more
  • MedWatch Drug Updates
  • 1 comment

Field Correction of system CS100, CS100i and CS300 Intra-Aortic Balloon Pumps by Datascope

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Clindamycin Injection USP ADD-Vantage vials by Alvogen: Presence of microbial growth

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Nitroglycerin Injection in 5% Dextrose USP by Advanced Pharma due to sub-potency

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Navigational accuracy errors associated with frameless stereotaxic navigation systems

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Paliperidone Extended-Release tablets, 3mg by Teva Pharmaceuticals due to failure of dissolution test

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of one lot Eliquis 5 mg tablets by Bristol-Myers Squibb- Contain product of incorrect strength

Read more
  • MedWatch Drug Updates
  • no comment

Recall of topical products by Phillips Company- Improper manufacturing practices affecting product's quality

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of all unexpired sterile drug products by Cantrell Drug Company- Lack of sterility assurance

Read more